Author: Newsdesk

– Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 –

IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX^® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that its Annual Shareholder Meeting will be held at 10:00 am Pacific Time (PT) on Wednesday, June 17, 2026 and will be held in the Company’s offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614. Meeting materials are expected to be made available to shareholders on or about April 29, 2026.

NYSE Required Disclosure Regarding Audit Opinion

As required by Section 610(b) of the NYSE American Company Guide, the Company also hereby provides notice that its audited consolidated financial statements for the fiscal year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K, contained an audit report from its independent registered public accounting firm that included a going concern qualification, which is not uncommon for development-stage biopharmaceutical companies with ongoing capital requirements. This disclosure does not reflect any change to the Company’s previously filed financial statements or the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The going concern qualification reflects the Company’s liquidity position as of the audit date. The Company expects its cash and cash equivalents to fund operations into the third quarter of 2026.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company seeking full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX^®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau^®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of botulinum toxin products. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON’s ability to continue to meet continued stock exchange listing standards; (ii) the Company’s planned annual shareholder meeting and any potential results thereof; (iii) the Company’s ability to obtain additional financing; (iv) the timing of making any Annual Shareholder Meeting materials available to shareholders; (v) the Company’s anticipated financial performance, including cash and cash equivalents; and (vi) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at


www.sec.gov


.

Contacts

Investor Contact:

Hershel Berry
Blueprint Life Science Group
[email protected]

Source: AEON Biopharma

ISELIN, N.J., April 24, 2026 (GLOBE NEWSWIRE) — Middlesex Water Company (NASDAQ: MSEX) announced today that its Board of Directors has declared a quarterly cash dividend of $0.36 per share on its common stock, payable June 1, 2026 to shareholders of record as of May 15, 2026. Middlesex has paid cash dividends in varying amounts continually since 1912.

About Middlesex Water Company

Middlesex Water Company (“Middlesex”) is one of the nation’s premier investor-owned water and wastewater utilities. Established in 1897, Middlesex is a trusted provider of life-sustaining services to more than half a million people in New Jersey and Delaware. The company focuses on employee engagement, operational excellence, superior customer experience, investment in infrastructure, and selective and sustainable growth to deliver value to our customers, investors, and the communities we serve.

Media Contact:

Summer DeFEO, Director of Communications
[email protected]
(732) 638-7510

Investor Contact:

Jennifer Ketschke, Director, Investor Relations and Treasury
[email protected]
(732) 638-7523

HONG KONG, April 24, 2026 (GLOBE NEWSWIRE) — DarkIris Inc. (Nasdaq: DKI) (the “Company” or “DarkIris”), a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games through various third-party digital storefronts, today announced the successful closing of a series of previously disclosed private placement and intellectual property (IP) assets acquisition. These include a $3.8 million private investment in public equity (PIPE) financing and an approximately $800,000 content acquisition of premium film and television IPs through equity issuance.

Through these transactions, DarkIris has introduced key industry partners into its business ecosystem, establishing a foundational collaboration framework to advance its AI-generated content (AIGC) closed-loop strategy across gaming and broader entertainment.

Key Highlights of the Transactions

Angel Investor Reinforces Commitment, Underscoring Market Confidence

Mr. Hong Chun’nan, an angel investor who has supported the Company ever since its inception, participated in the $3.8 million PIPE financing. His continued commitment reflects strong confidence in DarkIris’s strategic transformation toward an AIGC application ecosystem and its long-term commercial potential.

Strategic Gaming Partner Enhancing Ecosystem Synergies

CashGame Global PTE. LTD. (“CashGame Global”), a Singapore-based innovative game developer, also joined in the PIPE financing as a strategic investor and has closed its investment. This partnership brings a key player from the gaming industry into DarkIris’s pan-entertainment ecosystem, creating significant opportunities for commercial synergies, including prioritized collaboration on premium game titles and the integration of DarkIris’s proprietary AIGC production platform into CashGame Global’s game development pipeline.

$800K Content Acquisition Completed, Accelerating AI Film & TV Workflow Deployment

The Company has completed a short video drama purchase agreement with a seasoned Hong Kong-based film and television production house. As part of this transaction, the Company acquired a portfolio of 10 completed, high-quality film and television IP titles, valued at approximately $800,000. These newly acquired assets will be integrated into DarkIris’s proprietary AI video production workflow for post-production visual enhancement and special effects optimization, marking a scalable commercial deployment of the Company’s AI toolchain within traditional film and television post-production.

Management Commentary

Mr. Zhifang Hong, Chairman of the Board of DarkIris, commented: “The successful closing of these capital and asset transactions marks a significant and substantive step forward in the execution of DarkIris’s AIGC ecosystem strategy. Through targeted capital introduction, we have brought both gaming development and film production partners into our ecosystem, strengthening our pan-entertainment closed-loop vision. With capital support from our core shareholders and premium content assets now in place, our AIGC research and application center in Singapore now has robust liquidity support to accelerate the commercialization of our AI production workflows in real-world business scenarios.”

Invitation for Global Business Partnership

As DarkIris’s continue to advance and commercialize its AIGC production workflows, the Company sincerely invites game development studios, film and television content producers, and enterprises across the pan-entertainment sector to jointly explore collaboration opportunities. DarkIris seeks to empower content production pipelines through innovative AI technology, driving cost efficiencies and enabling deeper strategic partnerships.

For business development inquiries, please contact:

• Gaming Business: [email protected]
• AIGC Business: [email protected]

About DarkIris Inc.

DarkIris Inc. is a comprehensive technology enterprise based in Hong Kong, engaged in the development, publishing and operating of mobile digital games through various third-party digital storefronts. The Company conducts its business through its subsidiaries, Quantum Arts Co., Limited and Hongkong Stellar Wisdom Co., Limited. The Company’s activities include game design, programming and graphics, as well as the distribution and operation of mobile games across multiple platforms. DarkIris leverages (i) the innovative, creative and technical expertise of Hong Kong’s gaming industry community, and (ii) the multicultural environment and diverse interests of mobile game players in the regions. The Company’s goal is to create and promote a broader array of engaging, immersive, and captivating mobile game genres for a global audience. The Company is committed to consistently showcasing exceptional strength and unique allure across diverse gaming sectors, leading the way in pioneering advancements within the industry. For more information, please visit the Company’s website: www.darkiris.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions, the Company’s ability to comply with Nasdaq continued listing standards and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

DarkIris Inc.

Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
Phone: +1 646-932-7242
Email: [email protected]

NORWALK, Conn., April 24, 2026 (GLOBE NEWSWIRE) — Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced the appointment of Damian Warshall as Chief Operating Officer, effective April 27, 2026.

Mr. Warshall is a seasoned consumer packaged goods (CPG) operations executive with deep expertise in scaling beverage manufacturing operations, enhancing supply chain efficiency and driving profitable growth across complex organizations. Most recently, he served as Chief Operating Officer at Pittston Co-Packers, where he led the revitalization of a large-scale beverage manufacturing facility and secured a multi-million-dollar revenue pipeline. Prior to this, he served as Vice President of Operations at Munk Pack, leading production and commercialization initiatives, including a nationwide retail launch. Mr. Warshall is well known to Reed’s, having previously served as Vice President of Operations. He holds an M.B.A. from the University of Virginia’s Darden School of Business and a B.S.B.A. in Accounting and Finance from Georgetown University.

“Damian’s operational leadership and proven ability to build efficient, scalable manufacturing and supply chain systems position him well to enhance execution across our business operations,” said Neal Cohane, Interim Chief Executive Officer of Reed’s. “He brings a strong track record of driving operational discipline, improving cost structures and supporting profitable growth, which we believe will be critical as we continue to optimize our business. We believe his experience will be instrumental in strengthening our operational foundation, improving margins and creating long-term value for our shareholders.”

Mr. Warshall added, “I’m excited to return to Reed’s as Chief Operating Officer and to work alongside the team to further strengthen our operational capabilities. Our priorities will focus on driving efficiencies across our manufacturing and logistics network, increasing throughput, and enhancing execution with our partners. Delivering more consistent, scalable performance will be a central focus in 2026 and beyond as we continue to build a stronger, more efficient operating platform.”

About Reed’s, Inc.

Reed’s is an innovative company and category leader that provides the world with high quality, premium and better-for-you beverages. Established in 1989, Reed’s is a leader in craft beverages under the Reed’s^®, Virgil’s^® and Flying Cauldron^® brand names. The Company’s beverages are now sold in over 32,000 stores nationwide.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to implied or express statements regarding the anticipated contributions and impact of the executive appointment, and the Company’s expectations regarding its business strategies and plans and its ability to create long-term value for our shareholders. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors, including the risk factors and uncertainties described under the caption “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 25, 2026. The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law.

Investor Relations Contact

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
[email protected]
(720) 330-2829

• World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate
• Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026

CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.

To join the webcast, please visit the Events page of the Investors & Media section on Intellia’s website at intelliatx.com. A replay of the webcast will be available for approximately 90 days.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:


Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:


Mike Tattory
Vice President
LifeSci Communications
[email protected]

ATHENS, Greece, April 24, 2026 (GLOBE NEWSWIRE) — Heidmar Maritime Holdings Corp. (Nasdaq: HMR) (the “Company” or “Heidmar”), today announced that it has received written notification from The Nasdaq Stock Market (“Nasdaq”) dated April 22, 2026, indicating that because the closing bid price of the Company’s common stock for the last 30 consecutive business days was below the minimum US$1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the applicable grace period to regain compliance is 180 days, or until October 19, 2026.

The Company intends to monitor the closing bid price of its common stock during this grace period and will consider its options in order to regain compliance with The Nasdaq Capital Market minimum bid price requirement. The Company can cure this deficiency if the closing bid price of its common stock is US$1.00 per share or higher for at least ten consecutive business days during the grace period.

The Company intends to cure the deficiency within the prescribed grace period. During this time, the Company’s common stock will continue to be listed and trade on The Nasdaq Capital Market. The Company’s business operations are not affected by the receipt of the notification.

About the Company

Heidmar is an Athens based, commercial and pool management business servicing the crude and product tanker market and is committed to safety, performance, relationships and transparency. With operations in Athens, London, Singapore, Chennai, Hong Kong and Dubai, Heidmar has a reputation as a reliable and responsible partner with a goal of maximizing our customers’ profitability. Heidmar seeks to offer vessel owners a “one stop” solution for all maritime services in the crude oil, refined petroleum products and dry bulk shipping sectors. Heidmar believes its unique business model and extensive experience in the maritime industry allows the Company to achieve premier market coverage and utilization, as well as provide customers in the sector with seamless commercial transportation services. For more information, please visit www.heidmar.com.

Forward Looking Statements

This release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the Company. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s future results of operations and financial position, business strategy, prospective costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated operations of Heidmar are forward-looking statements. These forward- looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, Company management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include unforeseen liabilities, expansion and growth of the Company’s operations, the failure of counterparties to fully perform their contracts with the Company, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker, container or PSV vessel capacity, changes in the Company’s operating expenses, demand for the Company’s managed fleet, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general international geopolitical conditions and conflicts, potential disruption of shipping routes due to accidents or political events, vessel breakdowns and instances of off‐ hires, and other factors. Please see the Company’s filings with the U.S. Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.

CONTACT INFORMATION:

Investor Relations/Media Contact:

Nicolas Bornozis / Daniela Guerrero
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, N.Y. 10169
Tel.: (212) 661-7566
Email: [email protected]

NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) — At the end of the settlement date of April 15, 2026, short interest in 3,689 Nasdaq Global Market^SM securities totaled 16,579,123,734 shares compared with 16,513,796,397 shares in 3,694 Global Market issues reported for the prior settlement date of March 31, 2026. The mid-April short interest represents 2.71 days compared with 2.73 days for the prior reporting period.

Short interest in 1,643 securities on The Nasdaq Capital Market^SM totaled 3,919,142,444 shares at the end of the settlement date of April 15, 2026, compared with 3,881,873,664 shares in 1,642 securities for the previous reporting period. This represents a 1.16 day average daily volume; the previous reporting period’s figure was 1.30.

In summary, short interest in all 5,332 Nasdaq^® securities totaled 20,498,266,178 shares at the April 15, 2026 settlement date, compared with 5,336 issues and 20,395,670,061 shares at the end of the previous reporting period. This is 2.16 days average daily volume, compared with an average of 2.26 days for the prior reporting period.

The open short interest positions reported for each Nasdaq security reflect the total number of shares sold short by all broker/dealers regardless of their exchange affiliations. A short sale is generally understood to mean the sale of a security that the seller does not own or any sale that is consummated by the delivery of a security borrowed by or for the account of the seller.

For more information on Nasdaq Short interest positions, including publication dates, visit
https://www.nasdaq.com/market-activity/quotes/short-interest
or http://www.nasdaqtrader.com/asp/short_interest.asp.

About Nasdaq:

Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Media Contact:

Sam Raffalli
[email protected]

NDAQO

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/377c8039-1119-48e7-87bb-ccb2925710a5